(1) IN
GENERAL.—The directors of the Na-
tional Institute of Arthritis and Musculoskeletal and 
Skin Diseases and the National Institute of Allergy 
and Infectious Diseases shall continue to conduct 
and support research to expand understanding of 
the causes of, and to find a cure for, psoriasis and 
psoriatic arthritis, including the following: 
(A) Basic research to discover the patho-
genesis and pathophysiology of the disease. 
(B) Expansion of molecular biology and 
immunology studies, including additional animal 
models. 
(C) Global association mapping with single 
nucleotide polymorphisms. 
(D) Identification of environmental trig-
gers and autoantigens in psoriasis. 
(E) Elucidation of specific immunologic 
cells and their products involved. 
(F) Pharmcogenetic studies to understand 
the molecular basis for varying patient response 
to treatment. 
(G) Identification of genetic markers of 
psoriatic arthritis susceptibility. 
VerDate Nov 24 2008 
06:43 Feb 11, 2009
Jkt 079200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H930.IH
H930
jbell on PROD1PC69 with BILLS
(H) Research to increase understanding of 
joint inflammation and destruction in psoriatic 
arthritis. 
(I) Investigator-initiated clinical research 
for the development and evaluation of new 
treatments, including new biological agents. 
(J) Research to develop enhanced diag-
nostic tests that allow for earlier diagnosis of 
psoriasis and improved outcomes. 
(K) Research to increase understanding of 
the epidemiology and pathophysiology of co- 
morbidities associated with psoriasis, including 
shared molecular pathways. 
(2) 
COORDINATION
WITH
OTHER
INSTI-
TUTES.—In carrying out paragraph (1), the direc-
tors of the National Institute of Arthritis and Mus-
culoskeletal and Skin Diseases and the National In-
stitute of Allergy and Infectious Diseases shall co-
ordinate the activities of such Institutes with the ac-
tivities of other national research institutes and 
other agencies and offices of the National Institutes 
of Health relating to psoriasis or psoriatic arthritis. 
VerDate Nov 24 2008 
06:43 Feb 11, 2009
Jkt 079200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H930.IH
H930
jbell on PROD1PC69 with BILLS
SEC. 5. PSORIASIS AND PSORIATIC ARTHRITIS DATA COL-
LECTION AND NATIONAL PATIENT REGISTRY. 
The Secretary, acting through the Director of the 
Centers for Disease Control and Prevention and in col-
laboration with a national organization serving people with 
psoriasis and psoriatic arthritis, shall undertake psoriasis 
and psoriatic arthritis data collection and develop a psori-
asis and psoriatic arthritis patient registry. 
SEC. 6. NATIONAL SUMMIT. 
(a) IN GENERAL.—Not later than one year after the 
date of the enactment of this Act, the Secretary is encour-
aged to convene a summit on the Federal Government’s 
current and future efforts, and the initiatives necessary 
to fill any gaps, with respect to the conduct or support 
of psoriasis and psoriatic arthritis research, treatment, 
education, quality-of-life, and data collection activities. 
The summit should also address psoriasis and psoriatic 
arthritis related co-morbidities and should include re-
searchers, public health professionals, representatives of 
voluntary health agencies and patient advocacy organiza-
tions, representatives of academic institutions, representa-
tives from the pharmaceutical and medical research indus-
try, and Federal and State policymakers, including rep-
resentatives of the Agency for Healthcare Research and 
Quality, the Centers for Disease Control and Prevention, 
VerDate Nov 24 2008 
06:43 Feb 11, 2009
Jkt 079200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H930.IH
H930
jbell on PROD1PC69 with BILLS
the Food and Drug Administration, and the National In-
stitutes of Health. 
(b) FOCUS.—The summit convened under this section 
should focus on— 
(1) a broad range of research activities relating 
to biomedical, epidemiological, psychosocial, and re-
habilitative issues; 
(2) clinical research for the development and 
evaluation of new treatments, including new biologi-
cal agents; 
(3) translational research; 
(4) information and education programs for 
health care professionals and the public; 
(5) priorities among the programs and activities 
of the various Federal agencies involved in psoriasis 
and psoriatic arthritis and related co-morbidities; 
and 
(6) challenges, opportunities, and recommenda-
tions for scientists, clinicians, patients, and vol-
untary organizations. 
(c) REPORT TO CONGRESS.—Not later than 180 days 
after the first day of the summit convened under this sec-
tion, the Secretary shall submit to the Congress and make 
publicly available a report that includes a description of— 
(1) the proceedings at the summit; and 
VerDate Nov 24 2008 
06:43 Feb 11, 2009
Jkt 079200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H930.IH
H930
jbell on PROD1PC69 with BILLS
(2) recommendations related to the research, 
treatment, education, and quality-of-life activities 
conducted or supported by the Federal Government 
with respect to psoriasis and psoriatic arthritis, in-
cluding psoriasis and psoriatic arthritis related co- 
morbidities. 
SEC. 7. STUDY AND REPORT BY THE INSTITUTE OF MEDI-
CINE. 
(a) IN GENERAL.—The Secretary shall enter into an 
agreement with the Institute of Medicine to conduct a 
study on the following: 
(1) The extent to which public and private in-
surers cover prescription medications and other 
treatments for psoriasis and psoriatic arthritis. 
(2) The payment structures, such as deductibles 
and co-payments, and the amounts and duration of 
coverage under health plans and their adequacy to 
cover the costs of providing ongoing care to, and en-
sure access for, patients with psoriasis and psoriatic 
arthritis. 
(3) Health plan and insurer coverage policies 
and practices, including life-time caps, and their im-
pact on the access of such patients to the best regi-
men and most appropriate care for their particular 
disease state. 
VerDate Nov 24 2008 
06:43 Feb 11, 2009
Jkt 079200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H930.IH
H930
jbell on PROD1PC69 with BILLS
(b) REPORT.—The agreement entered into under 
subsection (a) shall provide for the Institute of Medicine 
to submit to the Secretary and the Congress, not later 
than 18 months after the date of the enactment of this 
Act, a report containing a description of— 
(1) the results of the study conducted under 
this section; and 
(2) the conclusions and recommendations of the 
Institute of Medicine regarding each of the issues 
described in paragraphs (1) through (3) of sub-
section (a). 
SEC. 8. AUTHORIZATION OF APPROPRIATIONS. 
To carry out this Act, there are authorized to be ap-
propriated such sums as may be necessary for each of fis-
cal years 2010 through 2014. 
Æ 
VerDate Nov 24 2008 
23:39 Feb 11, 2009
Jkt 079200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6301
E:\BILLS\H930.IH
H930
jbell on PROD1PC69 with BILLS